Assessment of Quality of Life Using Skindex-16 in Patients With Locally Advanced Basal Cell Carcinoma Treated With Vismodegib in the STEVIE Study
|
|
- Coral Williams
- 5 years ago
- Views:
Transcription
1 Assessment of Quality of Life Using Skindex-16 in Patients With Locally Advanced Basal Cell Carcinoma Treated With Vismodegib in the STEVIE Study Jean-Jacques Grob, 1 Karen Bartley, 2 Rainer Kunstfeld, 3 Brigitte Dréno, 4 Laurent Mortier, 5 Paolo Antonio Ascierto, 6 Caroline Dutriaux, 7 Nicolas Meyer, 8 Bernard Guillot, 9 Reinhard Dummer, 10 Sarah Williams, 11 Alberto Fittipaldo, 11 D. Scott Ernst, 12 Axel Hauschild, 13 Nicole Basset-Seguin, 14 Johan Hansson 15 1 Aix Marseille University Timone Hospital, Marseille, France; 2 Genentech, Inc., South San Francisco, CA, USA; 3 Medical University of Vienna, Vienna, Austria; 4 Nantes University, Nantes, France; 5 University of Lille 2, Lille Regional University Hospital, Lille, France; 6 Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy; 7 University Hospital of Bordeaux, Bordeaux, France; 8 Paul Sabatier University and Toulouse Cancer University Institute, Toulouse, France; 9 University Hospital of Montpellier, Montpellier, France; 10 University Hospital Zurich, Zurich, Switzerland; 11 Roche Products Ltd, Welwyn Garden City, UK; 12 Western University, London Regional Cancer Program, London, Ontario, Canada; 13 University Hospital Schleswig-Holstein, Kiel, Germany; 14 Université Paris Diderot Paris 7 and Hôpital Saint-Louis, Paris, France; 15 Karolinska Institutet, Stockholm, Sweden
2 Disclosures Dr. Grob declares the following conflicts of interest: Consulting/advising: Roche, GlaxoSmithKline, Bristol-Myers Squibb, Amgen, Merck, and Novartis Speakers bureau: GlaxoSmithKline Trial grants/research funding: Roche and Bristol-Myers Squibb This study was sponsored by F. Hoffmann-La Roche Ltd 2
3 Background STEVIE (ClinicalTrials.gov identifier, NCT ) is an ongoing phase 2 study to evaluate the safety of vismodegib in patients with labcc or mbcc 1 Skindex-16 assessments from an interim analysis of 499 patients of the efficacy-evaluable population with histologically confirmed disease are presented Objective To assess the disease burden related to BCC from the patients perspective using the Skindex-16 instrument Assessments were conducted at baseline, Cycle 2 Day 1, Cycle 7 Day 1, and end of study BCC, basal cell carcinoma; la, locally advanced; m, metastatic. 1. Basset-Seguin N et al. Lancet Oncol. 2015;16:
4 Study Design 1 mbcc labcc Vismodegib continual dosing 150 mg/day Until progression, intolerable toxicity, or withdrawal from study Safety follow-up Months 1, 3, 6, 9, and 12 Primary objective Safety Population size: 1200 patients planned 1232 patients enrolled Secondary objectives Overall response (based on RECIST), time to response, duration of response, progression-free survival, and overall survival HRQoL (as measured by Skindex-16) HRQoL, health-related quality of life; RECIST, Response Evaluation Criteria in Solid Tumors. 1. Basset-Seguin N et al. Lancet Oncol. 2015;16:
5 Effects of Skin Disease Skindex item patient-completed questionnaire whose items compose three domains (symptoms, emotional well-being, and functioning) Items are rated on a 7-point scale measuring the level of bother over the previous week, ranging from 0 (never bothered) to 6 (always bothered) Assessed at baseline, Cycle 2 Day 1, Cycle 7 Day 1, and end of study at a subset of clinical trial sites Decrease in score represents clinical improvement Clinically meaningful improvement defined as decrease of 10 points from baseline 1 Q, question. 1. Chren M-M et al. J Invest Dermatol. 2007;127: Symptoms (Q1-Q4) Itching Burning or stinging Hurting Being irritated Emotional Well-Being (Q5-Q11) Persistence/recurrence Worry Appearance Frustration Embarrassment Being annoyed Feeling depressed Functioning (Q12-Q16) Interactions with others Desire to be with people Show affection Daily activities Work or do what you enjoy 5
6 Patient Demographics labcc mbcc (n = 468) (n = 31) Male, % Mean age (years) ± SD 69.0 ± ± 12.9 Lesion location a n Head or neck, % Other, % BCCNS a n Yes, % Measurable disease n Yes, % a Reduced denominators are due to missing/unknown data. BCCNS, BCC nevus syndrome; SD, standard deviation. 6
7 Skindex-16 Scores at Baseline Items are rated on a 7-point scale measuring the level of bother over the previous week, ranging from 0 (never bothered) to 6 (always bothered) Responses to each item were transformed to a linear scale of 100, with higher scores indicating a greater level of bother (0 = never bothered, 100 = always bothered) Symptoms domain labcc (n = 455) mbcc (n = 29) Mean ± SD 22.9 ± ± 29.3 Median Emotional Well-Being domain Mean ± SD 47.9 ± ± 36.2 Median Functioning domain Mean ± SD 27.6 ± ± 30.8 Median
8 Median Skindex-16 Change From Baseline (points) Change in Emotional Well-Being Domain by labcc Subgroup Clinically meaningful improvements (decreases 10 points from baseline 1 ) in emotional well-being scores were observed across subgroups and time points No consistent differences were seen by gender and BCCNS status Improvements from baseline were consistently larger for patients with primary lesions in a location other than head/face or neck and for patients aged years This improvement was driven by large reductions in the level of bother related to the persistence/reoccurrence, worry, and appearance of patients skin conditions (data not shown) 0 Sex Emotional Well-Being Domain Age (years) BCCNS status Lesion location All patients Female Male >65 Yes No Head/neck Other 10 Clinically meaningful improvement Cycle 2 Cycle 7 EOS Cycle length = 28 days. EOS, end of study. 1. Chren M-M et al. J Invest Dermatol. 2007;127:
9 Median Skindex-16 Change From Baseline (points) Median Skindex-16 Score (points) Change in Symptoms and Functional Domains by labcc Subgroup Clinically meaningful deterioration 1 was not observed in either the symptoms or functioning domain in patients with labcc No clinically meaningful improvements 1 were seen for functional scores in patients with labcc (below) Symptoms Domain Functioning Domain Sex Age (years) BCCNS status All patients Female Male >65 Yes No 0 Lesion location Head/ neck Other Sex Age (years) BCCNS status All patients Female Male >65 Yes No 0 Lesion location Head/ neck Other Cycle 2 Cycle 7 EOS Clinically meaningful improvement Cycle 2 Cycle 7 EOS Clinically meaningful improvement Cycle length = 28 days. 1. Chren M-M et al. J Invest Dermatol. 2007;127:
10 Conclusions Skindex-16 scores at baseline indicate that patients with BCC experienced marked burden in their emotional well-being but were minimally bothered by how their BCC impacted their symptoms and functioning, suggesting that only the emotional well-being domain had a substantial impact on patients day-to-day lives at baseline Clinically meaningful improvements in emotional well-being were observed among patients with labcc at each postbaseline assessment; these improvements were driven by large reductions in the level of bother related to persistence/reoccurrence, worry about lesions, and appearance of lesions No consistent meaningful change, whether it be improvement or deterioration, was observed in the domains representing symptoms and functioning The sample size of patients with mbcc was limited; no meaningful improvement was seen at any time point across all domains Limitations Single-arm, open-label study Skindex-16 is a dermatology instrument that focuses on specific domains of disease burden as they relates to skin disease, but it does not comprehensively capture all relevant aspects of HRQoL (eg, treatment burden) Combined with the clinical efficacy data from this study, 1 the patient-reported findings from this large safety study support the effectiveness of vismodegib in the treatment of labcc 1. Basset-Seguin N et al. Lancet Oncol. 2015;16:
11 Acknowledgments We thank the investigators, patients, and current and past members of the Roche and Genentech vismodegib team Roche is developing vismodegib under a collaboration agreement with Curis, Inc. Vismodegib was discovered by Genentech and was jointly validated by Genentech and Curis through a series of preclinical studies Through this collaboration, Genentech (USA), Roche (outside the USA, excluding Japan and Korea), and Chugai Pharmaceuticals (Japan) are responsible for the clinical development and commercialization of vismodegib This analysis was funded by F. Hoffmann-La Roche Ltd. Third-party writing assistance for this poster was provided by ApotheCom (San Francisco, CA, USA) and was funded by F. Hoffmann-La Roche Ltd 11
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic, 1 MR Migden, 2 AE Oro, 3 L Dirix, 4 K Lewis,
More informationVismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial Nicole Basset-Seguin, Axel Hauschild, Jean-Jacques Grob, Rainer
More informationMayo School of Continuous Professional Development. Scott W. Fosko, M.D. Chair, Department of Dermatology Mayo Clinic Florida Jacksonville, Florida
Targeted Therapy Comes to BCC: Hedgehog Inhibitors Mayo School of Continuous Professional Development Scott W. Fosko, M.D. Chair, Department of Dermatology Mayo Clinic Florida Jacksonville, Florida 2016
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationThe Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma
The Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma Reinhard Dummer, 1 Keith Flaherty, 2 Richard Kefford, 3 Paolo A. Ascierto, 4 Laure Moutouh-de Parseval,
More informationAFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY
AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY Maximilian J. Hochmair, 1 Alessandro Morabito, 2 Desiree Hao, 3 Cheng-Ta Yang, 4 Ross A.
More informationBristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationVemurafenib in patients with BRAF V600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
Annals of Oncology : 51 5, 1 doi:1.193/annonc/mdx339 Published online August 1 ORIGINAL ARTICLE in patients with BRAF V6 mutation-positive metastatic melanoma: final overall survival results of the randomized
More informationRoche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer
Media Release Basel, 8 January 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer Higher expression of PD-L1 (programmed death-ligand 1)
More informationComparison of two HCV-RNA assays assessing early response to simeprevir+pegifn/rbv to select patients suitable to shorten therapy to 12 weeks
Comparison of two HCV-RNA assays assessing early response to simeprevir+pegifn/rbv to select patients suitable to shorten therapy to 12 weeks C Sarrazin, 1 M Buti, 2 C Moreno, 3 M Gschwantler, 4 GR Foster,
More information290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3
290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3 Presentation Number: 290O Lecture Time: 11:18-11:33 Speakers: Peter
More informationFrench Networks for Sarcoma and GIST. O Mir, JY Blay
French Networks for Sarcoma and GIST O Mir, JY Blay Introduction Since 2009 a network of 26 reference multidisciplinary centers aiming to improve the quality of care for sarcoma patients in France was
More informationJOURNAL OF CLINICAL ONCOLOGY R A P I D C O M M U N I C A T I O N
VOLUME 36 NUMBER 35 DECEMBER, 18 JOURNAL OF CLINICAL ONCOLOGY R A P I D C O M M U N I C A T I O N Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationJEADV ORIGINAL ARTICLE. Abstract
DOI: 10.1111/jdv.14542 JEADV ORIGINAL ARTICLE Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More information(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
More informationSummer AAD Summer AAD Support provided by LEO Pharma A/S. Poster nº
Support provided by LEO Pharma A/S Fixed combination calcipotriene plus betamethasone dipropionate aerosol foam provides improvement in quality of life and rapid relief of itch/itch-related sleep loss
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationPembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK /KEYNOTE-040)
A service of the U.S. National Institutes of Health Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials Trial
More informationSymptom Severity, Quality of Life and Work Productivity of US Psoriasis Patients During Periods of Flare and Remission
Symptom Severity, Quality of Life and Work Productivity of US Psoriasis Patients During Periods of Flare and Remission 93 Korman, NJ 1, Zhao, Y 2, Roberts, J 3 Pike, J 3, Lu, J 2, Tran, MH 2 (Please see
More informationImpact of ERBB mutations on clinical outcomes in afatinib- or erlotinib-treated patients with SqCC of the lung
Impact of ERBB mutations on clinical outcomes in afatinib- or erlotinib-treated patients with SqCC of the lung Glenwood D. Goss, Enriqueta Felip, 2 Manuel Cobo, 3 Shun Lu, 4 Konstantinos Syrigos, 5 Ki
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationESMO Symposium on Immuno-Oncology Programme book
IMMUNO-ONCOLOGY SYMPOSIUM ESMO Symposium on Immuno-Oncology Programme book Advances in cancer immunotherapy; From vaccines to antibodies and cell therapies Geneva Switzerland 15-16 NOVEMBER 2013 esmo.org
More informationJohn Strasswimmer MD, PhD
John Strasswimmer MD, PhD MIAMI CANCER 2018: NOVEL THERAPIES FOR BCC AND SCC OF SKIN AND MERKEL CELL CARCINOMA. MEDICAL DIRECTOR, MELANOMA & CUTANEOUS ONCOLOGY LYNN CANCER INSTITUTE - BOCA RATON REGIONAL
More informationVemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-5 Zurich www.zora.uzh.ch Year: 1 in patients with BRAFV mutation-positive metastatic melanoma: final overall
More informationPsoriasis Disease Severity Affects Patient Satisfaction With Therapy
82 Psoriasis Disease Severity Affects Patient Satisfaction With Therapy Korman NJ 1, Zhao Y 2, Tran MH 2, Lu J 2 (Please see authors affiliations on the last panel) Background Psoriasis is a chronic, immune
More informationGlobal Skin Cancer Diagnosis and Therapeutics Market Research and Forecast
Report Information More information from: https://www.wiseguyreports.com/reports/3186925-global-skin-cancer-diagnosis-and-therapeuticsmarket-research Global Skin Cancer Diagnosis and Therapeutics Market
More information2018 F. Hoffmann-La Roche Ltd. All rights reserved.
PRELIMINARY EVIDENCE FOR PHARMACODYNAMIC EFFECTS OF RG7916 IN JEWELFISH A STUDY IN PATIENTS WITH SPINAL MUSCULAR ATROPHY WHO PREVIOUSLY PARTICIPATED IN A STUDY WITH ANOTHER SMN2-SPLICING TARGETING THERAPY
More informationMedia Release. Basel, 29 September 2014
Media Release Basel, 29 September 2014 Roche s investigational combination of cobimetinib plus Zelboraf (vemurafenib) provided significant benefit to people with advanced melanoma over Zelboraf alone Cobimetinib
More informationIMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC
IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC Vassiliki A. Papadimitrakopoulou, 1 Manuel Cobo, 2 Rodolfo Bordoni, 3 Pascale
More informationMedia Release. Basel, 5 December 2016
Media Release Basel, 5 December 2016 Roche s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
More informationSUPPLEMENTARY DATA. Telediab Study Group :
Telediab Study Group : Guillaume Charpentier, MD, Department of Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France Centre d Études et de Recherches pour l Intensification du Traitement du Diabète
More informationWilhelminenspital, Vienna, Austria; 5 Queen Mary Hospital, University of London, Barts Health, London, UK; 6
Shortening overall treatment to 12 weeks of simeprevir plus PR in treatment-naïve chronic hepatitis C genotype 1 patients: assessment of baseline and Week 2 on-treatment predictors of SVR T Asselah, 1
More informationSecond European School of Dermato- Fundamentals of cutaneous oncology
Course Directors Prof. Sibel Alper, Istanbul, Turkey Prof. Claus Garbe, Tuebingen, Germany Second European School of Dermato- Oncology, organized by EADO: Fundamentals of cutaneous oncology www.dermato-oncology2014.org
More informationCombination of Roche medicines Cotellic and Zelboraf approved in Switzerland for the treatment of patients with advanced melanoma
Media Release Basel, 27 August 2015 Combination of Roche medicines Cotellic and Zelboraf approved in Switzerland for the treatment of patients with advanced melanoma New treatment option for patients with
More informationPoster Presented at the 2014 American College of Rheumatology Annual Meeting
Poster Presented at the 2014 American College of Rheumatology Annual Meeting Anne Winkler 1 James Mossell 2 Edmund MacLaughlin 3 Drew Johnson 4 J. Timothy Harrington 5 1 Winkler Medical Practice LLC, Springfield,
More informationLOTUS (NCT ) randomized phase II trial
Overall survival update of the double-blind placebocontrolled randomized phase 2 LOTUS trial of firstline ipatasertib + paclitaxel for locally advanced/metastatic triple-negative breast cancer Rebecca
More informationUniversity of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
More information79956F Kitano et al_bi754091bi TiP_JSMO 2018 (NB).pdf 1 13/07/ :55:06 C M Y CM MY CY CMY K
79956F Kitano et al_bi754091bi754111 TiP_JSMO 2018 (NB).pdf 1 13/07/2018 13:55:06 C M Y CM MY CY CMY K Phase 1 trial of an anti-pd-1 mab BI 754091 ± an anti-lag-3 mab BI 754111 in Asian patients with advanced
More informationMedia Release. Basel, 26 March 2018
Media Release Basel, 26 March 2018 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live
More informationEVATEL Study. Remote follow-up of patients implanted with an ICD The prospective randomized EVATEL study
EVATEL Study Remote follow-up of patients implanted with an ICD The prospective randomized EVATEL study Philippe Mabo, Pascal Defaye, Nicolas Sadoul, Jean Marc Davy, Jean-Claude Deharo, Salem Kacet, Eric
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationAppendices. Appendix A Search terms
Appendices Appendix A Search terms Database Search terms Medline 1. Ipilimumab; 2. MDX-010; 3. MDX-101; 4. Yervoy; 5. BMS-734016; 6. Nivolumab; 7. ONO-4538; 8. BMS-936558; 9. MDX-1106; 10. Opdivo; 11.
More informationPatients Driving Progress
Patients Driving Progress Ellen V Sigal, PhD WIN Symposium 2018 June 25, 2018 Paris, France Nothing to disclose The Evolution of Patient Advocacy The Agnew Clinic, Thomas Eakins (1899) Partial mastectomy
More informationrapid communication abstract
rapid communication Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial Celeste Lebbé,
More informationThe HeartQol questionnaire. Reliability, validity and responsiveness?
The HeartQol questionnaire. Reliability, validity and responsiveness? Stefan Höfer, PhD, MSc Associate Professor Medical University Innsbruck The HeartQoL Story Data collection: 2000 2010 Presentations:
More informationEvaluating Psoriasis: Patient Reported Outcomes and Impact of Disease
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Bruce E. Strober, MD, PhD Professor and Chair Department of Dermatology University of Connecticut Farmington, Connecticut DISCLOSURE
More informationImmunotherapy Bridge 2018 Naples November 28th-29th 2018 PRELIMINARY PROGRAM
Immunotherapy Bridge 2018 Naples November 28th-29th 2018 PRELIMINARY PROGRAM **Not included in the CME accredited program *invited/to be invited faculty November 28th (Wednesday) 08:30 09:00 Registration**
More informationCohort D Xentuzumab + abemaciclib + fulvestrant (500 mg/month) Key exclusion criteria RP2D-4 NSCLC. Cohort F Xentuzumab + abemaciclib + fulvestrant
A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy) Douglas
More informationLuana Calabrò Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori SIENA, ITALY
4 TH International Conference Traslational Research in Oncology Forli, November 10, 2016 Cytotoxic T-lymphocyte antigen-4 (CTLA-4) Luana Calabrò Medical Oncology and Immunotherapy, University Hospital
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationWhat s new in melanoma? Combination!
DOI 10.1186/s12967-015-0582-1 EDITORIAL Open Access What s new in melanoma? Combination! Paolo A Ascierto 1*, Francesco M Marincola 2 and Michael B Atkins 3 Abstract Melanoma was again a focus of attention
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, 2014 ClinicalTrials.gov ID: NCT00372385 Study Identification Unique Protocol ID: VX05-950-104EU Brief Title:
More informationSimilar risk of malignancy with insulin glargine and neutral protamine Hagedorn
Letter Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, openlabel study J. Rosenstock 1,2,
More informationDisclosure for Ralf Trappe, MD
Disclosure for Ralf Trappe, MD In compliance with ACCME policy, ASH requires the following disclosures to the session audience: Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau
More informationSan Antonio Breast Cancer Symposium December 8 12, 2015
PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib Plus in Postmenopausal Women With Endocrine-resistant HR+/HER2 Advanced Breast Cancer: First Results From the Randomized, Phase III
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Impact of Psoriasis Area and Severity Index (PASI) on patient reported outcomes in patients with psoriasis: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3,
More information4 th European School of Dermato-Oncology: Update on Cutaneous Oncology (ESDO)
4 th European School of Dermato-Oncology: Update on Cutaneous Oncology (ESDO) January 28 th 30 th, 2016 Berlin, Germany Course Directors Prof. Claus Garbe, Tuebingen, Germany Prof. Axel Hauschild, Kiel,
More informationMedia Release. Basel, 17 November 2012
Media Release Basel, 17 November 2012 Roche study showed that Avastin helped people with newly diagnosed glioblastoma live longer without their disease worsening when added to radiation and chemotherapy
More informationInternational medical oncologists, surgeons and radiation oncologists experienced in the management of head and neck cancer patients.
Aim of the educational preceptorship Treatment options for patients with unresectable head and neck cancer have been significantly expanded over the last few years. Combined modality treatment with concomitant
More informationMedia Release. Basel, 18 February 2017
Media Release Basel, 18 February 2017 Phase II study supports potential for Roche s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationREVISION DE LOS DATOS ACTUALES DE INMUNOTERAPIA EN MELANOMA. Miguel Ángel Cabrera Suárez Oncología médica HUNSC
REVISION DE LOS DATOS ACTUALES DE INMUNOTERAPIA EN MELANOMA Miguel Ángel Cabrera Suárez Oncología médica HUNSC Inmunoterapia en Melanoma Miguel Ángel Cabrera Suárez Oncologia médica HUNSC EL PASADO:
More informationPatients Perspective on the Impact of Moderate-to-Severe Genital Psoriasis
4664 Patients Perspective on the Impact of Moderate-to-Severe Genital Psoriasis Jennifer Clay Cather, 1 Alison Potts Bleakman, 2 April Naegeli, 2 Jiat Ling Poon, 3 Ashley Wallace, 4 Kristin Hollister,
More informationUniversity of California Los Angeles, Los Angeles, CA; 2. Department of Dermatology, University of Kiel, Kiel, Germany;
Final Efficacy Results of A3671009, a Phase III Study of Tremelimumab vs Chemotherapy (Dacarbazine or Temozolomide) in First-line Patients With Unresectable Melanoma Antoni Ribas, 1 Axel Hauschild, 2 Richard
More informationProlonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Original Article Prolonged Survival in Stage III Melanoma with Adjuvant Therapy A.M.M. Eggermont, V. Chiarion Sileni, J.-J. Grob, R. Dummer, J.D. Wolchok, H. Schmidt, O. Hamid, C. Robert, P.A. Ascierto,
More informationEuropean Commission approves Roche s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
Media Release Basel, 21 December 2017 European Commission approves Roche s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer Alecensa provides a new treatment option for people with
More informationThe European Dermatology Forum (EDF)
The European Dermatology Forum (EDF) A non-profit professional organization dedicated to improving the quality of healthcare for Dermatology patients in Europe www.euroderm.org European Dermatology Forum
More informationMedia Release. Basel, 7 May 2018
Media Release Basel, 7 May 2018 FDA grants priority review to Roche s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer Roche
More informationEvaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (CRISS) in the FaSScinate Trial
Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (CRISS) in the FaSScinate Trial D Khanna 1, V Berrocal 1, C Denton 2, A Jahreis 3, H Spotswood
More informationAn Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT )
An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) J.M. Xu a, J. Li b, C.M. Bai c, N. Xu d, Z.W. Zhou e, Z.P. Li f, C.C. Zhou g, W. Wang h, J. Li
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationTrial record 1 of 1 for:
Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: YO39523 Previous Study Return to List Next Study A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel,
More informationTitle A Phase II study of oral LBH589 in adult patients with refractory cutaneous T-Cell lymphoma
Sponsor Novartis Generic Drug Name Panobinostat Therapeutic Area of Trial Refractory cutaneous T-Cell lymphoma Approved Indication Investigational drug Protocol Number CLBH589B2201 Title A Phase II study
More informationDisclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationIs There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough?
Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough? Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA 1 Disclosure Ad Board: Genentech Honorarium:
More informationREAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO
REAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO Alain Ravaud, MD.PhD Bordeaux. France DISCLOSURES Consultant for: Pfizer, Novartis, GlaxoSmithKline, Roche, Bristol-Myers Squibb Institutional
More informationSequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
Scan the QR code for an electronic copy of the poster and supplementary material Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the
More informationMedia Release. Basel, 6 th February 2018
Media Release Basel, 6 th February 2018 Phase III IMmotion151 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain
More informationMedia Release. China National Drug Administration grants rapid approval of Roche s Alecensa (alectinib) as a treatment for ALK-positive lung cancer
Media Release China National Drug Administration grants rapid approval of Roche s Alecensa (alectinib) as a treatment for ALK-positive lung cancer Approval follows priority review of Alecensa in China,
More informationTechnology appraisal guidance Published: 22 November 2017 nice.org.uk/guidance/ta489
Vismodegib for treating basal cell carcinoma Technology appraisal guidance Published: 22 November 2017 nice.org.uk/guidance/ta489 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationA pilot study to determine the prevalence of HIV in individuals presenting for care with selected conditions:
A pilot study to determine the prevalence of HIV in individuals presenting for care with selected conditions: Preliminary results: the HIV in Europe Indicator Diseases Across Europe Study 10th International
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationOverview 2/11/18. Skin cancer surveillance after cancer therapy: When to worry. Skin cancer risk factors and types. Time to onset
Skin cancer surveillance after cancer therapy: When to worry Carrie C. Coughlin, MD Assistant Professor, Dermatology Washington University School of Medicine F072 - The Big C's: Children, Cancer, and Cutaneous
More informationRoche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma
Media Release Basel, 12 January 2017 Roche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma Administration time significantly reduced
More informationHHS Public Access Author manuscript N Engl J Med. Author manuscript; available in PMC 2017 November 22.
HHS Public Access Author manuscript Published in final edited form as: N Engl J Med. 2015 July 02; 373(1): 23 34. doi:10.1056/nejmoa1504030. Combined Nivolumab and Ipilimumab or Monotherapy in Previously
More informationOVERALL CLINICAL BENEFIT
cetuximab plus FOLFIRI to convert unresectable liver metastatses to resectable, perc confirmed that neither the FIRE-3 study nor the CRYSTAL study were designed to assess resectability and, in the absence
More informationA Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients
A Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients Viktor Grünwald, 1 David McDermott, 2 Michael Atkins, 3 Robert Motzer, 4
More informationThe vast majority of the two to three million
Skin Cancer: Important Developments in Treatment and Prevention As novel agents come to market or advance through phase III trials and new evidence emerges in the realm of chemoprevention, cancer therapy
More informationEfficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
4892 Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis ( Phase IV Study) Bruce Strober, MD 1 ; Jerry Bagel, MD 2 ; Mark Lebwohl, MD 3 ; Linda Stein Gold, MD 4 ; J. Mark Jackson,
More informationSaudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
More informationShelly A McNeil, MD on behalf of the SOS Network of the Canadian Immunization Research Network (CIRN) CIC 2016 Dec 6-8, 2016 Ottawa, ON
Resource Utilization and Cost of Laboratory Confirmed Influenza Requiring Hospitalization in Canadian Adults A Study from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research
More informationStudying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY)
A service of the U.S. National Institutes of Health Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY) This study is currently recruiting participants.
More informationSupplementary Online Content
Supplementary Online Content D Angelo SP, Russell J, Lebbé C, et al. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim
More informationEuropean Association for Cardiovascular Prevention & Rehabilitation (EACPR) A Registered Branch of the ESC
Quality of life of cardiac patients in Europe: HeartQoL Project Stefan Höfer The HeartQol Questionnaire: methodological and analytical approaches Patients Treatment Is quality of life important in cardiovascular
More informationInterpreting Prospective Studies
Comparative Effectiveness Research Collaborative Initiative (CER CI) PART 1: INTERPRETING OUTCOMES RESEARCH STUDIES FOR HEALTH CARE DECISION MAKERS ASSESSING PROSPECTIVE DATABASE STUDIES: A PROPOSED MEASUREMENT
More information